MA24484A1 - Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant . - Google Patents

Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .

Info

Publication number
MA24484A1
MA24484A1 MA24978A MA24978A MA24484A1 MA 24484 A1 MA24484 A1 MA 24484A1 MA 24978 A MA24978 A MA 24978A MA 24978 A MA24978 A MA 24978A MA 24484 A1 MA24484 A1 MA 24484A1
Authority
MA
Morocco
Prior art keywords
quinazolinones
atropisomers
aryl
preparation
compositions containing
Prior art date
Application number
MA24978A
Other languages
English (en)
Inventor
Michael Devries Keith
Mc Kowan Willard
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA24484A1 publication Critical patent/MA24484A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA24978A 1997-02-28 1998-02-25 Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant . MA24484A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3890597P 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
MA24484A1 true MA24484A1 (fr) 1998-10-01

Family

ID=21902563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24978A MA24484A1 (fr) 1997-02-28 1998-02-25 Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .

Country Status (40)

Country Link
US (1) US6306864B1 (fr)
EP (1) EP0968194B1 (fr)
JP (1) JP2000509731A (fr)
KR (1) KR100358636B1 (fr)
CN (1) CN1248248A (fr)
AP (1) AP859A (fr)
AR (1) AR011170A1 (fr)
AT (1) ATE267817T1 (fr)
AU (1) AU744028B2 (fr)
BG (1) BG103689A (fr)
BR (1) BR9807872A (fr)
CA (1) CA2282277C (fr)
DE (1) DE69824157T2 (fr)
DK (1) DK0968194T3 (fr)
DZ (1) DZ2440A1 (fr)
EA (1) EA001963B1 (fr)
ES (1) ES2219866T3 (fr)
GT (1) GT199800038A (fr)
HR (1) HRP980106A2 (fr)
HU (1) HUP0000914A3 (fr)
ID (1) ID22711A (fr)
IL (1) IL130900A0 (fr)
IS (1) IS1952B (fr)
MA (1) MA24484A1 (fr)
NO (1) NO313630B1 (fr)
NZ (1) NZ336628A (fr)
OA (1) OA11089A (fr)
PA (1) PA8447001A1 (fr)
PE (1) PE58399A1 (fr)
PL (1) PL335418A1 (fr)
PT (1) PT968194E (fr)
SK (1) SK113299A3 (fr)
TN (1) TNSN98035A1 (fr)
TR (1) TR199902093T2 (fr)
TW (1) TW504508B (fr)
UA (1) UA61097C2 (fr)
UY (1) UY24897A1 (fr)
WO (1) WO1998038173A1 (fr)
YU (1) YU41299A (fr)
ZA (1) ZA981666B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002905B1 (ru) 1996-05-15 2002-10-31 Пфайзер Инк. 2,3-двузамещенные-4(3н)-хиназолиноны и содержащая их фармацевтическая композиция
US6323208B1 (en) * 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―4―オン誘導体の製造方法
MXPA02010618A (es) * 2000-04-25 2004-05-05 Icos Corp Inhibidores de fosfatidilinositol 3-quinasa delta.
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
SI1288205T1 (sl) 2000-08-18 2011-05-31 Ajinomoto Kk Novi derivati fenilalanina
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
AU2004262533A1 (en) * 2003-08-08 2005-02-17 Ulysses Pharmaceutical Products Inc. Halogenated quinazolinyl nitrofurans as antibacterial agents
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
BRPI0418026A (pt) 2003-12-22 2007-04-17 Ajinomoto Kk derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
US7893260B2 (en) 2005-11-04 2011-02-22 Hydra Biosciences, Inc. Substituted quinazolin-4-one compounds for antagonizing TRPV3 function
WO2008041118A2 (fr) 2006-10-04 2008-04-10 Pfizer Products Inc. Dérivés de pyrido[4,3-d]pyrimidin-4(3h)-one utilisés en tant qu'antagonistes du récepteur calcique
WO2008140750A1 (fr) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Composés modulant la fonction du trp v3
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
WO2010057048A1 (fr) 2008-11-13 2010-05-20 Calistoga Pharmaceuticals Inc. Thérapies pour tumeurs malignes hématologiques
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
CN103275086B (zh) * 2013-05-30 2015-04-15 温州大学 一种6-取代喹唑啉并喹唑啉酮化合物及其合成方法和用途
SG11201604825VA (en) 2013-12-20 2016-07-28 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
US9533909B2 (en) 2014-03-31 2017-01-03 Corning Incorporated Methods and apparatus for material processing using atmospheric thermal plasma reactor
KR20170012560A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
DE102014217021A1 (de) * 2014-08-27 2016-03-03 Skf Lubrication Systems Germany Ag Gehäuse für eine Vorrichtung zum dosierten Verteilen eines Mediums sowie eine Dosiereinrichtung zur Verwendung in dem Gehäuse
EP3893844A1 (fr) 2018-12-14 2021-10-20 Eisai R&D Management Co., Ltd. Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine
CN115335050B (zh) 2020-01-29 2024-05-17 卡玛瑞制药有限公司 用于治疗皮肤病症的化合物和组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) * 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
GB9022785D0 (en) * 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (fr) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Quinazolones substituees a activite anticonvulsivante
US5777271A (en) * 1996-01-18 1998-07-07 Commscope, Inc. Cable having an at least partially oxidized armor layer
EA002905B1 (ru) * 1996-05-15 2002-10-31 Пфайзер Инк. 2,3-двузамещенные-4(3н)-хиназолиноны и содержащая их фармацевтическая композиция

Also Published As

Publication number Publication date
EA199900693A1 (ru) 2000-02-28
EP0968194A1 (fr) 2000-01-05
EP0968194B1 (fr) 2004-05-26
ES2219866T3 (es) 2004-12-01
CN1248248A (zh) 2000-03-22
BR9807872A (pt) 2000-03-21
DZ2440A1 (fr) 2003-01-11
TR199902093T2 (xx) 1999-12-21
ID22711A (id) 1999-12-09
IS1952B (is) 2004-10-13
NO994177D0 (no) 1999-08-27
OA11089A (en) 2003-09-22
PL335418A1 (en) 2000-04-25
AP859A (en) 2000-07-21
DE69824157T2 (de) 2004-10-14
HUP0000914A3 (en) 2001-09-28
AU744028B2 (en) 2002-02-14
KR100358636B1 (ko) 2002-10-31
HUP0000914A2 (hu) 2001-04-28
DK0968194T3 (da) 2004-08-16
AR011170A1 (es) 2000-08-02
NO313630B1 (no) 2002-11-04
EA001963B1 (ru) 2001-10-22
IS5140A (is) 1999-07-30
YU41299A (sh) 2002-09-19
NZ336628A (en) 2001-03-30
PT968194E (pt) 2004-08-31
NO994177L (no) 1999-08-27
KR20000075814A (ko) 2000-12-26
AP9801199A0 (en) 1998-03-31
TW504508B (en) 2002-10-01
AU5676898A (en) 1998-09-18
UY24897A1 (es) 2000-12-29
GT199800038A (es) 1999-08-13
UA61097C2 (uk) 2003-11-17
ZA981666B (en) 1999-08-27
ATE267817T1 (de) 2004-06-15
BG103689A (bg) 2000-11-30
HRP980106A2 (en) 1999-02-28
SK113299A3 (en) 2001-05-10
CA2282277A1 (fr) 1998-09-03
CA2282277C (fr) 2005-10-11
US6306864B1 (en) 2001-10-23
DE69824157D1 (de) 2004-07-01
IL130900A0 (en) 2001-01-28
PE58399A1 (es) 1999-06-16
TNSN98035A1 (fr) 2005-03-15
JP2000509731A (ja) 2000-08-02
PA8447001A1 (es) 2000-05-24
WO1998038173A1 (fr) 1998-09-03

Similar Documents

Publication Publication Date Title
MA24484A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant .
MA24529A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
MA23831A1 (fr) Derives de quinazoline, procede pour leur preparation et composition les contenant
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA23899A1 (fr) Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2045A1 (fr) Amides thérapeutiques, procédé pour leur préparation et compositions les contenant.
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26490A1 (fr) Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
MA26514A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26624A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.